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Introduction
Obesity and the associated health concerns have become popular topics in the medical
community due to the epidemic status they have reached in many developed countries. Obesity
creates significant economic stress due to medical costs, and also often leads to decreased life
expectancy and quality of life9. Obesity in humans is known to be linked to health issues
including insulin resistance, hypertension, and atherosclerosis which lead to serious
complications, including death9.
Atherosclerosis is an especially dangerous complication of obesity because it can lead to
obstruction of the arteries supplying blood to the heart. Diseases of the heart are the leading
cause of death in the United States, accounting for 25% of all deaths in the year 20074. Of these
heart disease related deaths, 66% resulted from ischemic (coronary artery) disease and 22%
resulted from acute myocardial infarction4. Both ischemic heart disease and myocardial
infarction are possible complications of atherosclerosis5. Because of the significant mortality
associated with this disease, research relating to atherosclerosis mechanisms as well as possible
treatments is of utmost importance.
The development of atherosclerosis occurs in several steps. The first step involves the
formation of a fatty streak, which occurs when lipoproteins are transported into the arterial walls.
This process is initially dependent on the difference in concentration of LDL cholesterol inside
and outside the cell and its interaction with the LDL receptor. Once the lipid is inside, the
development of plaques depends more on the retention of the lipid in the arterial wall, not the
rate of transport, regardless of concentration2.
The next step is oxidation of the lipids within the artery wall. This process occurs in two
phases; first, LDL is mildly oxidized by monocytes, then LDL is further oxidized by
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macrophages. One product of this oxidation, lysophosphatidylcholine, attracts monocytes and Tlymphocytes while simultaneously inducing vascular cell adhesion molecule-1 (VCAM-1) which
binds to these immune cells on the vascular wall5. Once strong oxidation occurs, LDL receptors
are impaired and lipids are transported into the cell without regard to concentration in the cell,
resulting in an abundance of lipids in the cytoplasm. These cells are referred to as foam cells
because of the foamy consistency the cytoplasm takes on2.
Once this fatty streak has formed, the lipid core may continue to expand and eventually
intrude into the lumen of the vessel. As the lipid core grows, proteinases begin to be secreted by
activated leukocytes, breaking down the extracellular matrix. Additionally, pro-inflammatory
cytokines including INF-tau can limit synthesis of new collagen. This causes the fibrous cap of
the vessel wall to weaken, making it susceptible to rupture. If the plaque ruptures, a thrombus
will form and occlude the artery. This can result in two outcomes: it may completely block the
vessel, resulting in a clinical event such as myocardial infarction, or if it only partially occludes
the lumen the thrombus may be repaired by thrombolysis and resorbed. This triggers a wound
healing response with release of platelet derived growth factor (PDGF) and transforming growth
factor-β (TGF-β), causing smooth muscle cells to proliferate and collagen to be produced as scar
tissue. This strengthens the fibrous cap on the vascular wall, but it also causes the blockage to
intrude further into the lumen. This leads to a more chronic condition such as ischemia5.
Atherosclerosis is an inflammatory disease that, in the past, was mainly considered a
degenerative disease which was not preventable2. Treatment mostly focused on prevention
through reduction of LDL cholesterol, and was not as effective as would be expected – reduction
of LDL levels typically results in only, at best, a one-third improvement over five years5. This
may be due in part to the fact that in developed nations, cholesterol levels that are considered
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average among the population still greatly exceed the normal level expected for humans
according to levels seen in animals as well as humans in agrarian societies5. Because of these
limitations of LDL cholesterol reduction, alternative methods to reduce atherosclerosis are
increasingly being considered.
Omega-3 Polyunsaturated Fatty Acids (PUFA) are one type of supplement that has
emerged as a possible prevention method for atherosclerosis. There are several mechanisms by
which Omega-3 PUFA have been shown to mediate atherosclerosis. One of these is the reduction
of plasma concentration of triglycerides and VLDL cholesterol. This reduces one of the main
initial triggers of atherosclerosis. Another mechanism is inhibition of thrombus formation by
substituting in the place of arachidonic acid on the endothelium. Arachidonic acid derived
metabolites have a tendency to be more prothrombotic and more vasoconstrictive than the
metabolites of Omega-3 PUFA. This process mediates the clot formation that can occlude the
vessel in atherosclerosis and prevents the lumen space from becoming smaller due to
vasoconstriction. However, this does not cause a drastic reduction in atherosclerosis3.
Mechanisms that may have more significant anti-atherosclerotic effects are the suppression of
inflammatory cytokines such as IL-1 and TNF in monocytes, reduction of PGDF production, and
reduction of adhesion factors responsible for the binding of immune cells such as VCAM-1.
These cytokine based mechanisms are the main focus of present studies of atherosclerosis
prevention because they are still not fully understood and they have strong potential as a
preventative measure for the process of atherosclerosis3.
Swine are increasingly being seen as a viable model for atherosclerosis in humans due to
their anatomical similarities, particularly in the cardiovascular system. The coronary vascular
system is similar to 90% of the human population, which makes development of coronary artery
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disease in pigs an excellent model for human coronary artery disease8. The metabolism of the pig
and its development of obesity have also been shown to be similar to humans. Swine are devoid
of brown fat postnatally and the size of the adipose tissue in swine is adequate for analysis of
samples through assays; this makes the swine model superior to rodent models used in the past8.
The purpose of this study is to develop a model of obesity-induced atherosclerosis similar
to that seen in humans. If successful, this swine model can be used to pursue possible treatments
for atherosclerosis as well as develop a more detailed understanding of the mechanisms behind
the gene expression control of progression of the disease. The pilot study will test the efficacy of
a 16 week trial of high fat diet in inducing atherosclerosis. This diet is expected to cause
significant increases in body weight, blood triglyceride and cholesterol levels, and development
of identifiable fatty plaques on the artery walls as shown in past studies of obesity correlated
conditions6. It would also be expected that inflammation would cause an increase in the stress
hormone, cortisol, and decreases in cortisol-inactivating Corticosteroid Binding Globulin (CBG)
resulting in a higher level of free, active cortisol in the bloodstream (Free Cortisol Index)1. The
first treatment that is being tested is supplementation of this high fat, atherosclerosis-inducing
diet with Omega-3 PUFA. Supplementation of the high fat diet with Omega-3 PUFA is expected
to mediate inflammation and the adverse health effects of the diet, including obesity, blood
triglyceride and cholesterol levels, cortisol and CBG levels and overall development of
atherosclerosis3.
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Materials and Methods:
Pilot study:
Two miniature swine from Sinclair Bio Resources7 were obtained at the age of 7 months,
both castrated males. Both were fed a high fat diet consisting of Purina Mills Laboratory MiniPig Breeder Chow (75% of diet) supplemented with Coconut Oil (17.2%), Corn Oil (2.3%),
Sodium Cholate bile salt (1.5%), and Cholesterol (4.0%). This diet was fed for 16 weeks.
Measures of body weight and fasting blood samples were taken at baseline and at 4 week
intervals afterward, and blood samples were analyzed for glucose levels, cholesterol and
triglyceride content, and cortisol and Corticosteroid Binding Globulin (CBG). Glucose was
measured at the time each sample was taken using a Glucometer. Cholesterol and triglycerides
were measured from the blood samples in the University of Tennessee Pathology Laboratory.
Cortisol was measured by Radioimmunoassay and Corticosteroid Binding Globulin was
measured by ELISA. Free Cortisol Index was obtained from the Cortisol to CBG ratio.
At baseline and at 4 week intervals, the pigs were sedated with ketamine (10 mg/kg) and
midazolam (0.4 mg/kg) intramuscularly and transported to the University of Tennessee Graduate
School of Medicine where Positron Emission Tomography (PET) and X-ray Computed
Tomography (CT) scans were taken. IV catheters were placed for anesthetic support as well as
administration of radiopharmaceutical and vascular contrast agent (1 ml/kg Omnipaque).
Tracheal intubation was also performed with administration of inhaled isofluorane/oxygen in
sternal recumbency for 60 minutes during the radiopharmaceutical uptake period and acquisition
of whole-body PET/CT images. The CT scans were used to find measurements of back fat depth
and abdominal and pericardial fat volume.
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At the conclusion of the 16 week study, the pigs were euthanized and a necropsy was
performed. Samples of liver, pancreas, thymus, spleen, visceral and subcutaneous fat, and artery
wall were obtained and flash frozen using liquid nitrogen. Sections of arteries were also taken
and preserved in formalin for future photography and examination.
Omega-3 PUFA study:
Eight miniature swine from Sinclair Bio Resources were obtained at the age of 7 months,
all castrated males. Four of these swine were fed the same high fat diet as in the pilot study as a
control group, while four were fed this high fat diet plus a supplement of Grow Mega fish oil.
One of the control pigs and one of the Omega-3 PUFA supplement pigs were each removed from
the study due to health concerns. One developed a gastric ulcer while the other developed an
upper respiratory infection; both were treated for these conditions and switched to a non-high fat
diet for the remainder of the study period. They were not included in the final data for either
group.
Measures of body weight and fasting blood samples were taken in 4 week intervals as
described in the pilot study. The PET and CT scans were not repeated for this study. At the
conclusion of the study, euthanasia and necropsy were performed as in the pilot study. Samples
of liver, pancreas, lymph node, thymus, spleen, subcutaneous and abdominal fat, and artery were
obtained and flash frozen using liquid nitrogen. Sections of arteries were also taken and
preserved in formalin for future photography and examination.
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Results and Discussion
Pilot Study

Figure 1: Body weights of the two minipigs over the course of the 16 week trial. The stated Pvalue indicates a significant difference between start and end of trial. Body weight showed a
consistent linear increase in both pigs. A pre-planned comparison between start- and end-points
revealed significant weight gains in these mature pigs. These results are compatible with what
was hypothesized for this high fat diet trial.

Figure 2: Circulating concentrations of plasma cholesterol (left) and triglycerides (right) The
stated P-value
value indicates a significant difference between start and end of trial.. Of particular
interest is the pig-to-pig
pig variation, which will need to be accounted for in future studies.
studies The
reason for the peak concentration at 88-12
12 weeks followed by a decrease is also unknown and will
require further investigation. The increases from baseline are compatible with what was
hypothesized for this high fat diet trial.
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Figure 3: Plasma concentrations of cortisol (top left), CBG (top right) and values for the Free
Cortisol Index (bottom). No significan
significantt change was observed in either plasma cortisol or the Free
Cortisol Index.
ndex. There was an observed increase in CBG from baseline to final measurement, but
because there is no correlation of the overall sequence of measurements no conclusions can be
drawn from this difference. It was hypothesized that increased inflammation would cause
cortisol to increase while CBG would decrease. This correlation was not proven in this trial.
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Figure 4: Circulating concentration of blood glucose after overnight fasting. No significant trend
or difference was observed in fasting blood glucose values from thee baseline values to the
conclusion of the experiment. This result was no
not as hypothesized, but did not affect
ffect the main
focus of the study, development of atherosclerosis. It was hypothesized that the high fat diet
would likely induce a diabetic or pre-diabetic insulin resistant condition, causing increases in
fasting blood glucose. This condition was not obs
observed in this 16 week trial. It is possible that
more obesity related health conditions such as this could occur over a longer time period, but
further investigation is needed in this area.
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Figure 5: Representative CT images showing increased backfat depth (white arrow, A and D),
pericardial fat volume (pink, A,C,D and F) and visceral fat volume (B,C,E and F) from the
beginning (A-C) to the end (D-F)
F) of the trial. These increases are compatible with what was
hypothesized for this high fat diet trial.
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Figure 6: Measures of back fat depth, abdominal fat volume, and pericardial fat volume as
obtained by CT scans. A significant increase was seen in all of these values, though there was
wide pig-to-pig
pig variation in pericardial fat volume for unknown reasons. The increases are
compatible with what was hypothesized for this high fat diet trial. Further investigation is needed
to determine the reason for the variation in the location of fat depots between pigs.

Table 1: Rates of accumulation
on of visceral (abdominal) and pericardial fat depots over the
course of the trial. Accumulation occurred in a linear fashion. These results are compatible with
what was hypothesized for this high fat diet trial.
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Figure 7: Representative
presentative cross sections of caudal aorta at the level of renal artery (left)
(left and
coronary artery (right). Near-total
total occlusion of the arteries occurred over the span of the 16 week
trial. This is a direct observation of the induction of atherosclerosis in this model. As
hypothesized, atherosclerotic plaques were created in this model.

Figure 8: Representative cross section of caudal aorta immediately distal to kidney (left)
(left and
representative longitudinal and cross sections of thoracic aorta (right). Near-total
total occlusion of
the caudal artery occurred over the span of the 16 week trial. This is a direct observation of the
induction of atherosclerosis in this model. As hypothesized, atherosclerotic plaques were created
in this model. Additionally,
ly, symptoms of peripheral artery disease were observed in these pigs,
showing evidence that these plaques caused ischemia of the caudal artery and possibly other
portions of the peripheral vascular system.
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Omega-3 PUFA Study

supplemented
Figure 9: Average values off body weight for high fat diet Control and PUFA-supplemented
groups. Over the course of the trial, the PUFA supplemented group had a lower body weight for
the most part. The PUFA group started out at a slightly higher average weight than the control
group, so this trend is not seen until week 8 of the trial. In terms of total gain, control
ontrol pigs tended
to gain more weight over the trial period than PUFA pigs did (21.2 ± 2.6 vs. 15.2 ± 0.9; p =
0.09). These results are all compatible with the hypothesi
hypothesiss that the PUFA diet would show less
weight gain than the high fat diet without supplementation.
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Figure 10: Plasma concentrations of cholesterol (top) and triglycerides (bottom). The pattern of
these values is similar to that seen in the pilot study
study, with a peak around 8-12
12 weeks and
subsequent decrease. Interestingly, the PUFA group had a higher concentration of both
cholesterol and triglycerides at the peak point, followed by a significant drop, putting the later
values lower than or equal to the control group. The reason for this is unknown and further
investigation is needed in this area. The overall increase in cholesterol and triglycerides is lower
in the PUFA group compared to the control, as hypothesized.
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Figure 11: Plasma concentrations of cortisol (top left), CBG (top right) and values for the Free
Cortisol Index (bottom). The results of these measurements do not follow the hypothesized
pattern.. Due to an expected decrease in inflammation with PUFA supplementation, the
concentration of cortisol would theoretically decrease while CBG would increase compared to
the control. In this trial, the opposite seems to have occurred, and the overall free cortisol
increased in the PUFA group. The reason for this is unknown. Testing for pro-inflammatory
inflammatory and
anti-inflammatory
inflammatory cytokines present in the blood, currently in progress, may explain this
discrepancy.

Omega-33 PUFA in the Obese Minipig

Hall

17

Figure 12: Circulating concentration of blood glucose after overnight fasting. Similar to the pilot
study, no statistically significant change in blood glucose was seen between the baseline and
final readings. The 16 week trial does not induce insulin resistance as was hypothesized, and
there is no significant difference between the PUFA and control groups.

Statistical analysis
Variables were analyzed in SAS (SAS Institute, Cary, NC, USA) with use of the mixed model
ANOVA. All data were analyzed with repeated measures. Least squares means were compared
with Fisher’s protected LSD. Significance was set at P ≤ 0.05, but trends when 0.10 ≥ P ≥ 0.05
were also noted in a priori comparisons of treatment effects at each time point. All figures depict
raw means and SEs.
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Discussion
This trial was successful in creating a model of obesity and atherosclerosis in swine that
is similar to that seen in humans, including clinical signs of ischemia. Both the pilot study and
the control group of the Omega-3 PUFA trial showed significant increases in body weight and
development of atherosclerosis. The Omega-3 supplementation trial had mixed results, with
body weight and cholesterol and triglyceride concentrations being decreased as expected, while
free cortisol showed the opposite result compared to what was hypothesized. Testing of gene
expression based pro-inflammatory and anti-inflammatory cytokines is currently in progress, and
may show more clearly what is occurring in terms of inflammation with Omega-3 PUFA
supplementation. Additionally, arterial samples from the Omega-PUFA study are currently being
analyzed as in the pilot study for plaque development. This may show more of the positive
effects of PUFA supplementation. The model for atherosclerosis that has been developed in this
experiment can be used for future treatment models as well as further investigation of the
molecular mechanisms of the development of atherosclerosis.
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